Hedge Fund Titans Bet Big on Drugmaker Shire’s Success

John Paulson, Dan Loeb, and other prominent Investors move into an industry in flux.

Illustration by Renaud Vigor.

For the past few years, Shire has been defined by two things: popular niche drugs and failed M&A.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.